Rhythm Pharmaceuticals

RYTM · NASDAQ

$90.20+$1.97 (+2.23%)TodayMarket closed · Oct 20, 7:32 PM ET

Prev close $88.23

Latest news

Press releaseOct 13, 7:30 PM ETGlobe Newswire
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Press releaseSep 28, 9:10 AM ETPRNewswire
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
Press releaseSep 22, 8:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
NewsSep 11, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
Press releaseSep 10, 8:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
Press releaseAug 24, 8:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Press releaseAug 17, 8:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
NewsAug 12, 1:18 PM ETVandana Singh
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Press releaseAug 11, 8:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Press releaseAug 4, 4:01 PM ETGlobe Newswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
NewsAug 4, 9:33 AM ET
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call
Press releaseAug 4, 7:01 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Press releaseJul 21, 5:10 PM ETPRNewswire
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
NewsJun 15, 12:51 PM ETVandana Singh
Why Is Rhythm Pharma Stock Jumping Today?
NewsMay 6, 2:04 PM ETAvi Kapoor
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
NewsMay 5, 9:09 AM ET
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseMay 5, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Press releaseMar 20, 12:58 PM ETPRNewswire
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
NewsMar 20, 9:40 AM ETVandana Singh
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
NewsMar 17, 12:19 PM ETAvi Kapoor
Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
NewsMar 17, 8:33 AM ETRishabh Mishra
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)
NewsMar 17, 8:08 AM ETAvi Kapoor
Microvast, Dragonfly Energy, Natural Gas Services And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsMar 17, 7:12 AM ETVandana Singh
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
NewsFeb 26, 7:06 AM ET
Insights into Rhythm Pharmaceuticals Q4 Earnings
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
NewsFeb 25, 12:01 PM ET
A Look Ahead: Rhythm Pharmaceuticals's Earnings Forecast
NewsFeb 19, 12:42 PM ETVandana Singh
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market
NewsDec 11, 1:17 PM ETVandana Singh
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
NewsDec 11, 12:18 PM ETAvi Kapoor
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday
Press releaseNov 4, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Press releaseAug 5, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsJul 9, 11:06 AM ETAvi Kapoor
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
Press releaseMay 7, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
NewsApr 13, 12:00 PM ETLekha Gupta
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
NewsApr 8, 10:37 AM ETAvi Kapoor
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
NewsApr 8, 9:22 AM ETAvi Kapoor
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Press releaseDec 20, 2:15 PM ETGlobe Newswire
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
NewsNov 4, 2:02 PM ET
What's Next: Rhythm Pharmaceuticals's Earnings Preview

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

10 Health Care Stocks With Whale Alerts In Today’s Session

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call

Earnings Scheduled For May 5, 2026

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy

Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)

Microvast, Dragonfly Energy, Natural Gas Services And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints

Insights into Rhythm Pharmaceuticals Q4 Earnings

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Earnings Scheduled For February 26, 2026

A Look Ahead: Rhythm Pharmaceuticals's Earnings Forecast

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Earnings Scheduled For August 5, 2025

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

What's Next: Rhythm Pharmaceuticals's Earnings Preview